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BACKGROUND: We previously reported that Trastuzumab- and Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity
(ADCC) in cancer patients was impaired in comparison with that in healthy donors because of NK-cell dysfunction. In this study, we
evaluated whether IL-21 could improve the impairment of ADCC in patients with oesophageal squamous cell carcinoma (ESCC), as
IL-21 was reported to have the ability to activate NK cells.
METHODS: We examined Trastuzumab- and Cetuximab-mediated ADCC of peripheral blood mononuclear cells (PBMCs) or of
enriched NK cells derived from ESCC patients (n¼20) and healthy donors (n¼16) in the presence of IL-21. We further analysed
ADCC-related molecules (perforin, granzyme-B, and CD247) on NK cells in response to IL-21.
RESULTS: Trastuzumab- and Cetuximab-mediated ADCC of PBMCs or of enriched NK cells was enhanced by the addition of IL-21 in a
dose-dependent manner and the levels of ADCC enhanced by IL-21 in patients were high enough in comparison with those in
healthy donors, paralleling the upregulation of CD247 on NK cells.
CONCLUSION: IL-21 could efficiently restore impaired ADCC in ESCC patients with the upregulation of CD247 molecules.
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Anti-HER2 mAb, Trastuzumab, was clinically demonstrated to
lead to a survival benefit in patients with HER2-overexpressing
breast cancer (Slamon et al, 2001; Hall and Cameron, 2009).
Moreover, anti-HER1 (EGFR) mAb, Cetuximab, has now been
approved for use in patients with colorectal cancer (Cunningham
et al, 2004; Saltz et al, 2004). In addition to breast and colon
cancer, HER-family overexpression has been identified in a variety
of human cancers such as gastrointestinal tract, colorectal, lung,
and bladder cancers, and is correlated in a wide variety of tumours
with progression (Neal et al, 1985; Yarden and Sliwkowski, 2001;
Takehana et al, 2002; Ooi et al, 2004). In particular, we and
others have reported that the overexpression of EGFR is present in
50–70% of oesophageal squamous cell carcinoma (ESCC) cases,
and is indicative of a poor prognosis (Itakura et al, 1994; Hanawa
et al, 2006). Moreover, we showed the overexpression of HER2 in
30% of ESCC cases (Mimura et al, 2005a). These results indicate
that ESCC cases show a relatively high incidence of EGFR and/or
HER2 overexpression, and that the HER family would be an
attractive target for the treatment of ESCC. Furthermore, we
showed in vitro that HER2- or EGFR-overexpressing ESCC was
killed by Trastuzumab- or Cetuximab-mediated antibody-depen-
dent cellular cytotoxicity (ADCC), respectively (Mimura et al, 2005b;
Kawaguchi et al, 2007a,b). Taken together, therapeutic mAbs such
as Trastuzumab and Cetuximab targeting the HER family
constitute an attractive approach in the treatment of ESCC.
There are many mechanisms that contribute to the anti-tumour
activity of Cetuximab and Trastuzumab, including a direct
inhibition of tyrosine kinase activity relating to the HER-family
signal, the inhibition of cell cycle progression, and increased levels
and activities of pro-apoptotic molecules (Sliwkowski et al, 1999;
Cuello et al, 2001). Furthermore, ADCC was proven to be one of
the important mechanisms of Trastuzumab, as it was reported that
the anti-tumour effects of Trastuzumab were dependent on the
presence of Fc receptor-bearing immune cells such as NK cells
(Clynes et al, 2000). In addition, it was clearly shown in a clinical
study that CD16 polymorphism, which is important in ADCC, was
significantly correlated with the outcome of Trastuzumab therapy
in breast cancer (Varchetta et al, 2007).
With regard to ADCC in patients with cancer, we reported that
Trastuzumab- and Cetuximab-mediated ADCC was impaired in
comparison with healthy donors because of NK-cell dysfunction
(Kono et al, 2002; Mimura et al, 2005b; Kawaguchi et al, 2007a). In
general, NK cells in cancer-bearing hosts are impaired by many
mechanisms, including their reduced number, imbalances in their
activating and inhibitory receptor repertoire, as well as immuno-
suppressive cytokines (Fan et al, 1997; Tsuruma et al, 1999). Thus,
the enhancement of NK-cell function may result in the improve-
ment of impaired ADCC in patients with cancer, leading to
successful treatment with Trastuzumab and Cetuximab. For
example, immunomodulatory cytokines, including interleukin
(IL)-2, IL-12, or IL-21, would be effective adjuvants in the
enhancement of impaired ADCC in patients with cancer.
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cells, and those produced by activated CD4 (þ) T and NKT cells
(Parrish-Novak et al, 2000; Coquet et al, 2007). Effects of IL-21
include activation of antigen-specific CTLs, activation and
differentiation of NK cells, and antibody production (Skak et al,
2008b). Furthermore, IL-21 has been shown to be an important
autocrine factor of Th17 cells (Nurieva et al, 2007). Interleukin-21
belongs to the common g-chain family, with a similarity to IL-2
and IL-21 in its sequence and structure (Asao et al, 2001).
Although the effect of IL-21 on murine NK cells has been
extensively elucidated (Skak et al, 2008b), there is still limited
information with regard to the effect of IL-21 on human NK cells.
There is a report that IL-21 enhanced human NK cytotoxicity
against K562, paralleling the upregulation of perforin and
granzyme (Skak et al, 2008a).
In this study, we evaluate whether IL-21 could improve the
impairment of ADCC mediated by Trastuzumab or Cetuximab in
patients with ESCC. Moreover, we further analysed the mechan-
isms behind how IL-21 enhanced ADCC, with particular focus on
functional molecules related to the cytotoxicity of NK cells.
MATERIALS AND METHODS
Patients
In all, 20 patients with oesophageal squamous cell carcinoma, who
were operated on in the University of Yamanashi Hospital from
2008 to 2009, were included in the study. The patients with
oesophageal cancer were 73.9±10.3 years old; 19 patients were
men and 1 was a women. A total of 6 patients belonged to stage I, 5
were stage II, 8 were stage III, and 1 was stage IV according to the
TNM classification for oesophageal cancers. None of the patients
received radiotherapy, chemotherapy, or other medical interven-
tions before the study. This study was approved by the ethical
committee of the University of Yamanashi, and written informed
consent was obtained from all individuals.
Cell lines
The ESCC cell lines KYSE30, KYSE50, and KYSE110 were purchased
from the Health Science Research Resources Bank (Osaka, Japan).
The ESCC cell line TE4 was a kind gift from Dr Nishihara (Institute of
Development, Aging and Cancer, University of Tohoku, Sendai,
Japan). All cells were cultured in RPMI 1640 medium with 5% fetal
bovine serum, 100Uml
 1 penicillin, 100mgml
 1 streptomycin, and
2mmoll
 1 L-glutamine. According to our previous studies (Mimura
et al, 2005b; Kawaguchi et al, 2007a,b), TE4 and KYSE50 were used as
high HER2- and low HER2-expressing tumours, respectively, and
KYSE30 and KYSE110 were used as high EGFR- and low EGFR-
expressing tumours, respectively.
Chemicals and antibodies
Humanised mouse anti-human EGFR antibody, Cetuximab
(Erbitux), was purchased from Merck (Dietikon, Switzerland).
The anti-HER-2 monoclonal antibody, Trastuzumab (Herceptin),
and anti-CD20 mAb Rituxan, which is an isotype-matched control
mAb, were purchased from Roche (Basel, Switzerland). Recombi-
nant human IL-21 was provided by Novo Nordisk (Copenhagen,
Denmark). Recombinant human IL-2 was purchased from
Peprotech (Rocky Hill, NJ, USA).
Preparation of cells
Peripheral blood mononuclear cells (PBMCs) were separated from
peripheral blood obtained from patients with ESCC and from
healthy donors by Ficoll-Paque (Pharmacia, Uppsala, Sweden)
density gradient centrifugation.
To prepare NK cells by negative selection, NK cells were isolated
from PBMCs by centrifugation with Ficoll-Paque after being
incubated with RosetteSep antibody cocktail for NK cells (StemCell
Technologies, Vancouver, British Columbia, Canada). The Roset-
teSep antibody cocktail was bound in bispecific antibody
complexes, which are directed against cell-surface antigens on
human haematopoietic cells (CD3, CD4, CD19, CD36, and CD66b)
and glycophorin A on red blood cells. Unwanted cells, which
adhered to red blood cells, and desired cells were separated using a
Ficoll-Paque density gradient.
IL-21 treatment of PBMCs or NK cells
Peripheral blood mononuclear cells (1 10
6cellsml
 1) or NK cells
(1 10
6cellsml
 1) were incubated with X-VIVO medium in
48-well culture plates in the presence or absence of IL-21 for 24h.
ADCC assay
After the target cells were labelled with 50mCi of
51Cr for 60min,
target cells (5 10
3 per well) and PBMCs or NK cells as effector
cells were co-incubated at various effector:target ratios in 200mlo f
X-VIVO medium in a 96-well U-bottomed plate in triplicate with
Trastuzumab (10mgml
 1), Cetuximab (5mgml
 1), or control mAb
Rituxan. After 6h of incubation, radioactivity of the supernatant
(100ml) was measured with a g-counter. The percentage of specific
lysis¼100 (experimental c.p.m. spontaneous c.p.m.)/(maximum
c.p.m. spontaneous c.p.m.).
Flow cytometry
For the expression of CD247 (transducing z molecule) on NK cells,
PBMCs were stained with CD56-FITC (DAKO, Glostrup, Denmark)
and CD3-APC (DAKO). Thereafter, the stained cells were fixed
with 0.25% formaldehyde in PBS for 10min, followed by
permeabilisation with digitonin (Invitrogen, Carlsbad, CA, USA;
10mgml
 1) for 15min on ice, and stained with anti-CD247 mAbs
conjugated with PE (IMMUNOTEC, Marseille, France) or with
IgG1 isotype control mAbs for 10min on ice. The mean
fluorescence intensity for CD247 gated on CD56(þ)CD3( ) cells
was assessed by flow cytometric analysis.
For the expression of perforin and granzyme-B on NK cells,
PBMCs were stained with CD56-FITC and CD3-APC. Thereafter,
the stained cells were fixed and permeabilised using the Cytoperm/
Cytofix kit (BD Bioscience, San Diego, CA, USA), followed by
staining with mouse anti-human perforin mAbs conjugated with
FITC (BD Pharmingen, San Diego, CA, USA) or mouse anti-human
Granzyme-B mAbs conjugated with FITC (BD Pharmingen). The
mean fluorescence intensity for perforin or granzyme-B gated on
CD56(þ)CD3( ) cells was assessed by flow cytometric analysis.
For the expression of IL-21 receptor (IL-21R) on NK cells,
PBMCs were stained with CD56-FITC, CD3-APC, and PE-labelled
anti-human IL-21R mAb (R&D Systems, Minneapolis, MN, USA).
Statistical analysis
Paired and non-paired Student’s t-tests were used to examine the
differences between groups. Findings were considered significant
when P-values were o0.05.
RESULTS
Trastuzumab- and Cetuximab-mediated ADCC was
impaired in patients with ESCC
We examined Trastuzumab- and Cetuximab-mediated ADCC of
PBMCs derived from patients and healthy donors. High EGFR-
expressing KYSE30 and low EGFR-expressing KYSE110 were killed
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the degree of EGFR expression, as shown in Figure 1A (high EGFR-
expressing KYSE30 vs low EGFR-expressing KYSE110). It is
noteworthy that the levels of Cetuximab-mediated ADCC in
patients with ESCC were significantly impaired in comparison
with those in healthy donors (Figure 1A), in line with our previous
reports (Kawaguchi et al, 2007a).
Similarly, HER2-expressing ESCC tumour cells were efficiently
killed by Trastuzumab-mediated ADCC, with PBMCs derived from
patients and healthy donors, and the ADCC activity reflected the
degree of HER2 expression, as shown in Figure 1B (high HER-2-
expressing TE4 vs low HER-2-expressing KYSE50). It is important
to note that the levels of Trastuzumab-mediated ADCC in patients
with ESCC were significantly impaired in comparison with those in
healthy donors (Figure 1B), in line with our previous report
(Mimura et al, 2005b).
Taken together, we confirmed that Trastuzumab- and Cetux-
imab-mediated ADCC was impaired in patients with ESCC in
comparison with those in healthy donors, although HER2-
expressing or EGFR-expressing ESCC was killed by Trastuzumab-
and Cetuximab-mediated ADCC, respectively.
IL-21 enhanced Cetuximab-mediated ADCC activity of
PBMCs derived from ESCC patients
We next analysed the effect of IL-21 on Cetuximab-mediated
ADCC, when PBMCs derived from patients and healthy donors
were cultured with IL-21 at indicated doses for 24h. Representative
ADCC data showed that Cetuximab-mediated ADCC activity was
significantly enhanced by the addition of IL-21 to PBMCs derived
from patients and healthy donors (Figure 2A). Summarised data
from patients (n¼12) and healthy donors (n¼10) clearly showed
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Figure 1 Trastuzumab- and Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) of peripheral blood mononuclear cells
(PBMCs) from patients and healthy donors. (A) Cetuximab-mediated ADCC of PBMCs from patients (oesophageal squamous cell carcinoma (ESCC),
n¼12) and healthy donors (healthy, n¼10) was analysed against high EGFR-expressing KYSE30 and low EGFR-expressing KYSE110 cells in the presence of
Cetuximab or control mAbs at the indicated effector:target ratios (10:1, 20:1, and 40:1). *Po0.05. (B) Trastuzumab-mediated ADCC of PBMCs from
patients (ESCC, n¼8) and healthy donors (healthy, n¼6) was analysed against high HER2-expressing TE4 and low HER2-expressing KYSE50 cells in the
presence of Trastuzumab or control mAbs at the indicated effector:target ratios (10:1, 20:1, and 40:1). *Po0.05. The expression of EGFR or HER2 on
target tumour cells was shown as mean fluorescence intensity (MFI) analysed by flow cytometry.
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against high EGFR-expressing KYSE30 and low EGFR-expressing
KYSE110 in a dose-dependent manner (Figure 2B). It is
noteworthy that Cetuximab-mediated ADCC enhanced by IL-21
in patients was high enough in comparison with that in healthy
donors; for example, 75.1±7.3 vs 82.2±8.2%, respectively at an
E:T ratio of 40:1 and 10mgml
 1 of IL-21 against KYSE30
(Figure 2B), in which the original ADCC levels of patients were
significantly impaired in comparison with those of healthy donors
(Figure 1A). Thus, IL-21 could efficiently enhance impaired
Cetuximab-mediated ADCC in patients with ESCC.
IL-21 enhanced Trastuzumab-mediated ADCC activity of
PBMCs derived from ESCC patients
We further investigated the effect of IL-21 on Trastuzumab-
mediated ADCC, when PBMCs derived from patients and healthy
donors were cultured with IL-21 at indicated doses for 24h.
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Figure 2 Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) of peripheral blood mononuclear cells (PBMCs) cultured with IL-
21. PBMCs derived from patients (oesophageal squamous cell carcinoma (ESCC)) and healthy donors (healthy) were cultured with IL-21 at the indicated
doses (1, 5, and 10mgml
 1) for 24h. Thereafter, cultured PBMCs were subjected to Cetuximab-mediated ADCC against high EGFR-expressing KYSE30 and
low EGFR-expressing KYSE110 at the indicated effector:target ratios (10:1, 20:1, and 40:1). (A) Representative data showed that Cetuximab-mediated
ADCC was enhanced by the addition of IL-21. (B) Summarised data from patients (ESCC, n¼12) and healthy donors (healthy, n¼10) showed that IL-21
significantly enhanced Cetuximab-mediated ADCC in a dose-dependent manner. **Po0.01. The expression of EGFR on target tumour cells was shown as
mean fluorescence intensity (MFI) analysed by flow cytometry.
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sRepresentative ADCC data indicated that Trastuzumab-mediated
ADCC activity was significantly enhanced by the addition of IL-21
to PBMCs derived from patients and healthy donors (Figure 3A).
Summarised data from patients (n¼8) and healthy donors (n¼6)
clearly showed that IL-21 could significantly enhance Trastuzu-
mab-mediated ADCC activity against high HER2-expressing
TE4 and low HER2-expressing KYSE50 in a dose-dependent
manner (Figure 3B). It is important to note that the ADCC
enhanced by IL-21 in patients was high enough in comparison with
that in healthy donors; for example, 62.7±10.5 vs 74.9±4.3%,
respectively at an E:T ratio of 40:1 and 10mgml
 1 of IL-21 against
TE4 (Figure 3B), in which the original ADCC levels in patients were
significantly impaired in comparison with those in healthy donors
(Figure 1B). Thus, the enhancement by IL-21 of impaired ADCC in
patients was also confirmed with regard to Trastuzumab-mediated
ADCC.
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Figure 3 Trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) of peripheral blood mononuclear cells (PBMCs) cultured with
IL-21. PBMCs derived from patients (oesophageal squamous cell carcinoma (ESCC)) and healthy donors (healthy) were cultured with IL-21 at the indicated
doses (1, 5, and 10mgml
 1) for 24h. Thereafter, cultured PBMCs were subjected to Trastuzumab-mediated ADCC against high HER2-expressing TE4 and
low HER2-expressing KYSE50 at the indicated effector:target ratios (10:1, 20:1, and 40:1). (A) Representative data showed that Trastuzumab-mediated
ADCC was enhanced by the addition of IL-21. (B) Summarised data from patients (ESCC, n¼8) and healthy donors (healthy, n¼6) showed that IL-21
significantly enhanced Trastuzumab-mediated ADCC in a dose-dependent manner. **Po0.01. *Po0.05. The expression of HER2 on target tumour cells
was shown as mean fluorescence intensity (MFI) analysed by flow cytometry.
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As the use of purified NK cells vs PBMC cultures might influence
the effect of IL-21 because of the presence of accessory cells, we
further analysed the effect of IL-21 on ADCC mediated by NK cells,
when enriched NK cells were cultured with IL-21 at indicated doses
for 24h. NK cells from healthy donors (n¼7) were enriched using
a negative selection kit and were confirmed to be more than 93%
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Figure 4 Cetuximab- and Trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) of NK cells cultured with IL-21. Purified NK cells
derived from healthy donors (n¼7) were cultured with IL-21 at indicated doses (1, 5, and 10mgml
 1) for 24h. Thereafter, cultured NK cells were subjected to
an ADCC assay against high EGFR-expressing KYSE30 and low EGFR-expressing KYSE110 at the indicated effector:target ratios (5:1, 10:1, and 20:1) in the
presence of Cetuximab or control mAbs (Control, A). Similarly, the cultured NK cells were subjected to an ADCC assay against high HER2-expressing TE4 and
low HER2-expressing KYSE50 at the indicated effector:target ratios (5:1, 10:1, and 20:1) in the presence of Trastuzumab or control mAbs (Control, B).
**Po0.01. *Po0.05. The expression of HER2 or EGFR on target tumour cells was shown as mean fluorescence intensity (MFI) analysed by flow cytometry. In
(C), purified NK cells derived from healthy donors were cultured with IL-21 (1 and 10mgml
 1)o rI L - 2( 2 0a n d2 0 0n gm l
 1) for 24h. The cultured NK cells were
subjected to an ADCC assay against high HER2-expressing TE4 or high EGFR-expressing KYSE30 at the indicated effector:target ratios (5:1, 10:1, and 20:1)in
the presence of Trastuzumab or Cetuximab. Representative ADCC assay from three different experiments from healthy donors (n¼3) was shown in (C).
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showed that Cetuximab-mediated ADCC of NK cells was enhanced
by the addition of IL-21 against both high EGFR- and low EGFR-
expressing ESCC (Figure 4A). Similarly, Trastuzumab-mediated
ADCC of NK cells was enhanced by the addition of IL-21 against
both high HER2- and low HER2-expressing ESCC (Figure 4B).
These results indicated that IL-21 directly affected NK cells,
leading to ADCC enhancement.
Furthermore, the enhancement of ADCC induced by IL-21 was
compared with those induced by IL-2. Enriched NK cells from
healthy donors (n¼3) were cultured with IL-21 or IL-2 at
indicated doses for 24h and subjected to ADCC assay. As a result,
Cetuximab-mediated ADCC against high EGFR-expressing
KYSE30 induced by IL-21 (1 and 10mgml
 1) was comparable to
those induced by IL-2 (20 and 200ngml
 1) (Figure 4C). Similarly,
Trastuzumab-mediated ADCC against high HER2-expressing TE4
was comparable to those induced by IL-2 (Figure 4C). This
observation was confirmed in three different experiments with NK
cells from different healthy donors (n¼3).
Alteration of ADCC-related molecules on NK cells in
response to IL-21
We further analysed how IL-21 enhances ADCC with particular
focus on ADCC-related molecules on NK cells. As it has been
reported that CD247 molecules (signal-transducing z molecules)
on NK cells were related to CD16 (Fc receptor)-related cytotoxicity
(Whiteside, 2004), we evaluated the expression of CD247 molecules
on NK cells (CD56(þ)CD3( )), analysed by intracellular staining
with flow cytometry, when PBMCs in patients with ESCC were
treated with IL-21. Representative flow cytometric and sum-
marised data (n¼12) indicated that the expression of CD247 on
NK cells was significantly enhanced by treatment with IL-21 at
5mgml
 1 (Figure 5).
Next, as it has been shown that IL-21 increased perforin
and granzyme-B (Skak et al, 2008a), we evaluated their expression
on NK cells by intracellular staining with flow cytometry,
when PBMCs (n¼8) from patients were treated with IL-21.
As shown in Figure 6, the expression of perforin or granzyme-B
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Figure 5 Upregulation of CD247 on NK cells in response to IL-21.
Peripheral blood mononuclear cells (PBMCs) derived from patients
(n¼12) were cultured with IL-21 at the indicated doses (1 and 5mgml
 1)
for 24h. Thereafter, the expression of CD247 molecules on NK cells
(CD56(þ)CD3( )) was analysed by intracellular staining with flow
cytometry. Representative data of flow cytometry and summarised data
(n¼12) indicated that the expression of CD247 on NK cells was
significantly enhanced by treatment with IL-21 at 5mgml
 1.
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Figure 6 Perforin and granzyme-B on NK cells cultured with IL-21. Peripheral blood mononuclear cells (PBMCs) derived from patients (n¼8) were
cultured with IL-21 at the indicated doses (1, 5, and 10mgml
 1) for 24h. Thereafter, the expression of perforin and granzyme-B molecules on NK cells
(CD56(þ)CD3( )) was analysed by intracellular staining with flow cytometry. Representative data of flow cytometry and summarised data are shown.
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son NK cells was not significantly enhanced by the addition of IL-21
in the present setting.
Expression of IL-21 receptor on NK cells
Peripheral blood mononuclear cells were stained with anti-IL-21
receptor (IL-21R) mAbs in combination with anti-CD56 and anti-
CD3 mAbs, and the percentage of IL-21R(þ) cells gated on
CD56(þ)CD3( ) cells was analysed by flow cytometry. Repre-
sentative flow cytometric data indicated that the frequency of IL-
21R-positive NK cells in a patient with ESCC was increased in
comparison with that in a healthy donor (Figure 7A). Summarised
data from healthy donors (n¼5) and ESCC patients (n¼5)
showed that IL-21R-positive NK cells were significantly increased
in ESCC patients compared with healthy donors (Figure 7B).
DISCUSSION
This study provided important and novel findings that IL-21 could
efficiently restore impaired ADCC in ESCC patients with the
upregulation of CD247 molecules.
There is increasing evidence that ADCC is one of the important
mechanisms behind therapeutic mAbs such as Trastuzumab and
Cetuximab, which have an anti-tumour effect (Clynes et al, 2000;
Varchetta et al, 2007). However, we and others reported that ADCC
activity was downregulated in patients with cancer, mainly because
of NK-cell dysfunction, compared with that in healthy donors
(Kono et al, 2002; Mimura et al, 2005b; Kawaguchi et al, 2007a).
Thus, ADCC enhancement in patients may lead to successful
treatment with therapeutic mAbs such as Trastuzumab and
Cetuximab. For example, immunomodulatory cytokines including
IL-21R
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Figure 7 Expression of IL-21 receptor on NK cells. Peripheral blood mononuclear cells (PBMCs) were stained with anti-IL-21 receptor (IL-21R) mAb in
combination with anti-CD56 and anti-CD3 mAbs, and the percentage of IL-21R(þ) cells gated on CD56(þ)CD3( ) cells was analysed by flow cytometry.
Representative flow cytometric data are shown in (A). Summarised data from healthy donors (healthy, n¼5) and oesophageal squamous cell carcinoma
(ESCC) patients (n¼5) are shown in (B).
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sIL-2, IL-12, or IL-21 would be effective adjuvants in the
enhancement of impaired ADCC in patients with cancer. In a
previous study, IL-21 was reported to have the ability to enhance
ADCC or NK activity in human in vitro models (Skak et al, 2008a).
In this study, we provided clear evidence, for the first time, that
IL-21 could efficiently restore impaired ADCC mediated by
Trastuzumab and Cetuximab in patients with ESCC. These results
encourage us to apply combination therapy of therapeutic mAbs
with IL-21.
Although the effect of IL-21 on murine NK cells has been
extensively elucidated, there is still limited information about the
effect of IL-21 on human NK cells (Skak et al, 2008b). IL-21 had
only moderate effects on surface levels of inhibitory (CD158a and
CD158b) and activating NK-cell receptors (NKG2D) in human NK
cells (Skak et al, 2008a). Moreover, IL-21 was able to increase both
mRNA and protein levels of the effector molecules perforin and
granzyme-B, as well as enhance NK cytotoxicity against K562
(Skak et al, 2008a). In this study, we provided novel findings that
IL-21 induced the significant upregulation of CD247 molecules on
NK cells, important molecules for Fc receptor (CD16)-dependent
NK killing (Whiteside, 2004). These results suggested that the
upregulation of CD247 molecules was one of the mechanisms
behind IL-21-enhanced ADCC in patients with ESCC. However, we
did not detect the upregulation of perforin and granzyme-B in
response to IL-21 treatment in this study. Although the reason for
this discrepancy is currently unknown, it may be due to the
difference in in vitro culture condition, for example, unfractio-
nated PBMCs vs purified NK cells, or incubation time.
In this study, we showed that IL-21 could directly act on NK
cells, as one of the mechanisms behind IL-21 enhances ADCC
activity, as it was shown that purified NK cells treated with IL-21
could enhance ADCC activity. In addition, it was previously shown
that IL-21 indirectly enhanced NK cell function through cytokine
production such as IFN-g, when PBMCs were treated with IL-21
(Roda et al, 2007). Thus, it is likely that IL-21 has pleiotrophic
roles in a wide variety of cells, leading to the enhancement of
ADCC activity (Roda et al, 2006).
In this study, we showed that the highest dose of IL-21 was
sometimes less effective for the enhancement of ADCC than IL-21
at lower levels. It is likely that there might be some plateau effect of
IL-21 at the highest dose in some patients, although further
experiments are needed to clarify the mechanisms.
A phase I study involving IL-21 monotherapy for metastatic
melanoma or renal cell carcinoma reported that monotherapy was
well tolerated and exhibited anti-tumour activity in some patients
(Davis et al, 2007; Thompson et al, 2008), thereby suggesting that
IL-21 may have an anti-tumour effect as a monotherapy. However,
this study clearly showed that IL-21 could efficiently enhance
impaired ADCC activity in ESCC patients, suggesting that
combination therapy of Trastuzumab or Cetuximab with IL-21
might result in the enhancement of the anti-tumour effect.
Furthermore, it was previously shown that the combination of
IL-2 and IL-21 could induce additional effects on the enhancement
of ADCC activity (Skak et al, 2008a). Thus, immunomodulatory
cytokines including IL-2, IL-12, or IL-21 would be effective
adjuvants in the enhancement of impaired ADCC in patients with
cancer.
Regarding the IL-21R on NK cells, we showed in this study that
IL-21R-positive NK cells were significantly increased in ESCC
patients than in healthy donors. This observation indicated that
IL-21 is capable of inducing NK-cell activation in patients with
ESCC. Furthermore, the observation for upregulated IL-21R was
also found in NK cells of patients with inflammatory bowel disease
(IBD) (Liu et al, 2009), suggesting that the expression of IL-21R on
NK cells may be upregulated in response to chronic inflammatory
reactions such as IBD or ESCC. The response to IL-21 is also
affected by a polymorphism in the IL-21R gene (Pe `ne et al, 2006).
Moreover, dimorphism in the gene encoding FcgRIIIa influences
the binding affinity between the Fc receptor (CD16) and mAbs
(Wu et al, 1997). These observations suggest that genetic factors
might have an important role in determining the clinical efficacy of
therapeutic mAbs when a cytokine adjuvant is used. In this study,
the levels of IL-21-enhanced ADCC mediated by PBMCs did not
markedly differ among patients or healthy donors. However, it
may be important to evaluate genetic factors such as polymorph-
ism of the IL-21R gene or FcgRIIIa in patients when clinical trials
with mAbs in combination with IL-21 are initiated.
In conclusion, IL-21 could efficiently restore impaired ADCC in
patients with ESCC, suggesting that the combination therapy of
Trastuzumab or Cetuximab with IL-21 might lead to an enhance-
ment of the anti-tumour effect.
ACKNOWLEDGEMENTS
This study was supported by a grant from the Ministry of
Education, Culture, Sports, Science, and Technology of Japan. We
thank Novo Nordisk for providing rIL-21.
Conflicts of interest
The authors declare no conflict of interest.
REFERENCES
Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D, Sugamura K
(2001) Cutting edge: the common gamma-chain is an indispensable
subunit of the IL-21 receptor complex. J Immunol 167: 1–5
Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors
modulate in vivo cytotoxicity against tumor targets. Nat Med 6: 443–446
Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, Smyth MJ,
Godfrey DI (2007) IL-21 is produced by NKT cells and modulates NKT
cell activation and cytokine production. J Immunol 178: 2827–2834
Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis
PA, Lipkowitz S (2001) Down-regulation of the erbB-2 receptor by
trastuzumab (herceptin) enhances tumor necrosis factor-related apop-
tosis-inducing ligand-mediated apoptosis in breast and ovarian cancer
cell lines that overexpress erbB-2. Cancer Res 61: 4892–4900
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets
D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-
refractory metastatic colorectal cancer. N Engl J Med 351: 337–345
Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, Moller NP,
Skak K, Lundsgaard D, Frederiksen KS, Thygesen P, McArthur GA
(2007) An open-label, two-arm, phase I trial of recombinant human
interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 13:
3630–3636
Fan QR, Mosyak L, Winter CC, Wagtmann N, Long EO, Wiley DC (1997)
Structure of the inhibitory receptor for human natural killer cells
resembles haematopoietic receptors. Nature 389: 96–100
Hall PS, Cameron DA (2009) Current perspective-trastuzumab. Eur
J Cancer 45: 12–18
Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A
(2006) EGFR protein overexpression and gene amplification in squamous
cell carcinomas of the esophagus. Int J Cancer 118: 1173–1180
Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S, Nagura H
(1994) Epidermal growth factor receptor overexpression in esophageal
carcinoma. An immunohistochemical study correlated with clinico-
pathologic findings and DNA amplification. Cancer 74: 795–804
IL-21 enhances ADCC in cancer patients
M Watanabe et al
528
British Journal of Cancer (2010) 102(3), 520–529 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sKawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H (2007a)
Cetuximab induce antibody-dependent cellular cytotoxicity against
EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer
120: 781–787
Kawaguchi Y, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, Fujii H
(2007b) Targeting EGFR and HER2 with cetuximab- and trastuzumab-
mediated immunotherapy in oesophageal squamous cell carcinoma.
Br J Cancer 97: 494–501
Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y (2002)
Impaired antibody-dependent cellular cytotoxicity mediated by hercep-
tin in patients with gastric cancer. Cancer Res 62: 5813–5817
Liu Z, Yang L, Cui Y, Wang X, Guo C, Huang Z, Kan Q, Liu Z, Liu Y (2009)
Il-21 enhances NK cell activation and cytolytic activity and induces Th17
cell differentiation in inflammatory bowel disease. Inflamm Bowel Dis 15:
1133–1144
Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A, Fujii
H (2005a) Frequencies of HER-2/neu expression and gene amplification
in patients with oesophageal squamous cell carcinoma. Br J Cancer 92:
1253–1260
Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A, Fujii H
(2005b) Trastuzumab-mediated antibody-dependent cellular cytotoxicity
against esophageal squamous cell carcinoma. Clin Cancer Res 11:
4898–4904
Neal DE, Marsh C, Bennett MK, Abel PD, Hall RR, Sainsbury JR, Harris AL
(1985) Epidermal-growth-factor receptors in human bladder cancer:
comparison of invasive and superficial tumours. Lancet 1: 366–368
Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns
K, Tian Q, Watowich SS, Jetten AM, Dong C (2007) Essential autocrine
regulation by IL-21 in the generation of inflammatory T cells. Nature 448:
480–483
Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y,
Dobashi Y (2004) Protein overexpression and gene amplification of HER-
2 and EGFR in colorectal cancers: an immunohistochemical and
fluorescent in situ hybridization study. Mod Pathol 17: 895–904
Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA,
Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M,
Brandt C, Kuijper JL, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F,
Bort S, Hambly K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton-Day C,
Gilbert T, Rayond F, Ching A, Yao L, Smith D, Webster P, Whitmore T,
Maurer M, Kaushansky K, Holly RD, Foster D (2000) Interleukin 21 and
its receptor are involved in NK cell expansion and regulation of
lymphocyte function. Nature 408: 57–63
Pe `ne J, Guglielmi L, Gauchat JF, Harrer N, Woisetschla ¨ger M, Boulay V,
Fabre JM, Demoly P, Yssel H (2006) IFN-gamma-mediated inhibition of
human IgE synthesis by IL-21 is associated with a polymorphism in the
IL-21R gene. J Immunol 177: 5006–5013
Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S,
Carson III WE (2007) The activation of natural killer cell effector
functions by cetuximab-coated, epidermal growth factor receptor
positive tumor cells is enhanced by cytokines. Clin Cancer Res 13:
6419–6428
Roda JM, Parihar R, Lehman A, Mani A, Tridandapani S, Carson III WE
(2006) Interleukin-21 enhances NK cell activation in response to
antibody-coated targets. J Immunol 177: 120–129
Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ (2004)
Phase II trial of Cetuximab in patients with refractory colorectal cancer
that expresses the epidermal growth factor receptor. J Clin Oncol 22:
1201–1208
Skak K, Frederiksen KS, Lundsgaard D (2008a) Interleukin-21 activates
human natural killer cells and modulates their surface receptor
expression. Immunology 123: 575–583
Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV (2008b)
Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug
Discov 7: 231–240
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming
T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of
chemotherapy plus a monoclonal antibody against HER2 for metastatic
breast cancer that overexpresses HER2. NE n g lJM e d344: 783–792
Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA
(1999) Nonclinical studies addressing the mechanism of action of
trastuzumab (Herceptin). Semin Oncol 26: 60–70
Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y,
Fujino MA, Ooi A (2002) Status of c-erbB-2 in gastric adenocarcinoma: a
comparative study of immunohistochemistry, fluorescence in situ
hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer
98: 833–837
Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS,
Sievers EL, Hughes SD, DeVries TA, Hausman DF (2008) Phase I study of
recombinant interleukin-21 in patients with metastatic melanoma and
renal cell carcinoma. J Clin Oncol 26: 2034–2039
Tsuruma T, Yagihashi A, Hirata K, Torigoe T, Araya J, Watanabe N, Sato N
(1999) Interleukin-10 reduces natural killer (NK) sensitivity of tumor
cells by downregulating NK target structure expression. Cell Immunol
198: 103–110
Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS,
Villani L, Tagliabue E, Me ´nard S, Costa A, Fagnoni FF (2007) Elements
related to heterogeneity of antibody-dependent cell cytotoxicity in
patients under trastuzumab therapy for primary operable breast cancer
overexpressing Her2. Cancer Res 67: 11991–11999
Whiteside TL (2004) Down-regulation of zeta-chain expression in T cells: a
biomarker of prognosis in cancer? Cancer Immunol Immunother 53:
865–878
Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE,
Kimberly RP (1997) A novel polymorphism of Fc gamma RIIIa (CD16)
alters receptor function and predisposes to autoimmune disease. J Clin
Invest 100: 1059–1070
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network.
Nat Rev Mol Cell Biol 2: 127–137
IL-21 enhances ADCC in cancer patients
M Watanabe et al
529
British Journal of Cancer (2010) 102(3), 520–529 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s